Mirtazapine Bluefish Pharmceuticals

Mirtazapine, the active ingredient in Mirtazapine Bluefish, is a noradrenergic and specific serotonergic antidepressant (NaSSA) presented as a strength/form not specified for oral use. It is indicated for the treatment of major depressive disorder in adult patients.

GNH USA supplies Mirtazapine Bluefish as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Mirtazapine acts on the central nervous system to alleviate depressive disorders. It is primarily prescribed for the following conditions:

- Major depressive disorder: reduces depressive symptoms and improves mood in adults. - Depression with insomnia: helps restore sleep quality while treating depressive symptoms. - Depression with anxiety features: may lessen anxiety alongside mood improvement.

Mirtazapine is associated with a range of adverse reactions.

Common Side Effects: - Sedation or drowsiness. - Increased appetite leading to weight gain. - Dry mouth. - Constipation. - Dizziness. - Peripheral edema.

Serious or Rare Side Effects: - Agranulocytosis or severe neutropenia. - Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Suicidal thoughts or behavior, especially early in treatment. - Seizures. - Hepatic dysfunction. - Severe hypersensitivity reactions.

When prescribing or dispensing Mirtazapine, consider the following precautions: - Monitor weight: patients may experience significant weight gain. - Assess for suicidal ideation: close observation is needed during treatment initiation. - Caution in hepatic impairment: dose adjustment may be required. - Avoid abrupt discontinuation: tapering helps prevent withdrawal symptoms. - Pregnancy and lactation: use only if potential benefits outweigh risks. - Store at ambient temperature below 25°C: keep in the original container, protect from moisture and light.

Mirtazapine may interact with several drug classes.

Major Interactions (Avoid): - Concomitant use with MAO inhibitors: risk of hypertensive crisis. - Combined with CNS depressants (e.g., benzodiazepines, opioids): may enhance sedation and respiratory depression. - Potent CYP2D6 inhibitors (e.g., fluoxetine, paroxetine): can increase mirtazapine plasma concentrations.

Moderate Interactions (Monitor Closely): - Other serotonergic agents (e.g., SSRIs, SNRIs): potential for serotonin syndrome. - Antihistamines: additive sedative effects. - Alcohol: may intensify central nervous system depression.